The Zhitong Finance App learned that Nurix Therapeutics (NRIX.US) continued its previous post-market decline before Wednesday after announcing that its partner SNY.US (SNY.US) decided to stop an experimental inflammatory disease treatment study. At press time, Nurix was down 32.96% to $17.31.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.